Success of Immunopathogenetic Therapy for Management of Congenital Ichthyosis, Combined Form, in a Child: Rare Clinical Case

Background. Congenital ichthyosis (CI) is relating to the group of clinical and genetically heterogeneous severe genodermatoses. SAM syndrome is included in classification of CI syndromic forms. Defects in the desmoplakin (DSP) and desmoglein 1 (DSG1) genes are the prime cause of disease. Impaired function of encoded proteins leads to desmosomal anomalies and disease symptoms. Comorbid atopic syndrome becomes the major cause of diagnostic mistakes. Patients are observed continuously with diagnosis “Atopic dermatitis (AD) torpid to standard treatment methods”. Clinical case description. This article describes a rare case of a boy with severe AD. Despite the chronic dermatosis several systemic disorders were revealed during examination: short stature, protein-energy malnutrition, adrenal insufficiency, juvenile polyarthritis, vitamin D deficiency, onychodystrophy, dysmorphic disorders. Molecular genetic study conducted via high-throughput sequencing followed by validation with Sanger sequencing has revealed two genetic variants: novel variant chr18:28934543G>T in the DSG1 gene in the heterozygous state and pathogenic variant chr5:157468728C>A in the NIPAL4 gene in the homozygous state. As a result, the final diagnosis was established: “SAM syndrome. Congenital ichthyosiform erythroderma”. Flow cytometry immunology study has shown dominant immunological profile of Th17-, and Thact-lymphocyte proliferation. The immunobiological therapy with IL-17A inhibitor, secukinumab, was initiated. Clinical efficacy was evaluated via ISS (Ichthyosis Severity Index), CDLQI (Children’s Dermatology Life Quality Index), pruritus numerical rating scale. ISS was 5.8 points, pruritus scale — 9, CDLQI — 24 at therapy initiation. Improvement in the skin condition was observed after a month of therapy. ISS was 1.2 points, pruritus scale — 2, CDLQI — 4 6 months after the therapy initiation. Conclusion. The diagnosis of a child with combined form of CI made it possible to change the management strategy, to prescribe pathogenetically justified targeted immunobiological therapy, and to achieve significant improvement in the child's health and quality of life, which does not differ from healthy peers.

1. Murashkin NN, Avetisyan KO, Ivanov RA, Makarova SG. Congenital Ichthyosis: Clinical and Genetic Characteristics of the Disease. Voprosy sovremennoi pediatrii — Current Pediatrics. 2022;21(5):362–377. (In Russ). doi: https://doi.org/10.15690/vsp.v21i5.2459

2. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol. 2010;63(4):607–641. doi: https://doi.org/10.1016/j.jaad.2009.11.020

3. Avetisyan KO, Murashkin NN, Makarova SG, et al. Features of Cell-Mediated Immunity in Children with Congenital Ichthyosis and Their Role in the Pathogenetic Management. Voprosy sovremennoi pediatrii — Current Pediatrics. 2023;22(5):415–424. (In Russ). doi: https://doi.org/10.15690/vsp.v22i5.2645

4. Vahlquist A, Törmä H. Ichthyosis: A Road Model for Skin Research. Acta Derm Venereol. 2020;100(7):adv00097. doi: https://doi.org/10.2340/00015555-3433

5. Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet. 2013;45(10):1244–1248. doi: https://doi.org/10.1038/ng.2739

6. Ballin N, Hotz A, Bourrat E, et al. Genetical, clinical, and functional analysis of a large international cohort of patients with autosomal recessive congenital ichthyosis due to mutations in NIPAL4. Hum Mutat. 2019;40(12):2318–2333. doi: https://doi.org/10.1002/humu.23883

7. McGrath JA. Inherited disorders of desmosomes. Australas J Dermatol. 2005;46(4):221–229. doi: https://doi.org/10.1111/j.1440-0960.2005.00188.x

8. Vakkilainen S, Puhakka L, Klemetti P, et al. Novel DSP Spectrin 6 Region Variant Causes Neonatal Erythroderma, Failure to Thrive, Severe Herpes Simplex Infections and Brain Lesions. Acta Derm Venereol. 2019;99(9):789–796. doi: https://doi.org/10.2340/00015555-3203

9. Cohen-Barak E, Godsel LM, Koetsier JL, et al. The Role of Desmoglein 1 in Gap Junction Turnover Revealed through the Study of SAM Syndrome. J Invest Dermatol. 2020;140(3):556–567.e9. doi: https://doi.org/10.1016/j.jid.2019.08.433

10. Körner RW, Velmans C, Dückers G, Tantcheva-Poór I. First observation of dupilumab efficacy in an infant with SAM (severe dermatitis, multiple allergies and metabolic wasting) syndrome. J Eur Acad Dermatol Venereol. 2023;37(10):e1200–e1202. doi: https://doi.org/10.1111/jdv.19185

11. Keren H, Bergman R, Mizrachi M, et al. Diffuse nonepidermolytic palmoplantar keratoderma caused by a recurrent nonsense mutation in DSG1. Arch Dermatol. 2005;141(5):625–628. doi: https://doi.org/10.1001/archderm.141.5.625

12. Pan C, Cheng R, Li Y, et al. Deep-intronic and frameshift DSG1 variants associated with atypical severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome in a Chinese family. Eur J Dermatol. 2021;31(2):239–244. doi: https://doi.org/10.1684/ejd.2021.4012

13. Singh S, Singh S, Mehta H, et al. Unravelling the mystery: severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome with a novel homozygous mutation in DSG1. Clin Exp Dermatol. 2024;49(6):624–626. doi: https://doi.org/10.1093/ced/llae026

14. Paller AS, Czarnowicki T, Renert-Yuval Y, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. J Am Acad Dermatol. 2018;78(3):498–505.e2. doi: https://doi.org/10.1016/j.jaad.2017.10.026

15. McAleer MA, Pohler E, Smith FJ, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol. 2015;136(5):1268–1276. doi: https://doi.org/10.1016/j.jaci.2015.05.002

16. Taiber S, Samuelov L, Mohamad J, et al. SAM syndrome is characterized by extensive phenotypic heterogeneity. Exp Dermatol. 2018;27(7):787–790. doi: https://doi.org/10.1111/exd.13551

17. Cheng R, Yan M, Ni C, et al. Report of Chinese family with severe dermatitis, multiple allergies and metabolic wasting syndrome caused by novel homozygous desmoglein-1 gene mutation. J Dermatol. 2016;43(10):1201–1204. doi: https://doi.org/10.1111/1346-8138.13431

18. Srinivas SM, Basavanaik P, Gowdra A. A novel homozygous frameshift mutation in DSG1 gene in an Indian consanguineous family with severe dermatitis, multiple allergies and metabolic wasting syndrome. Indian J Dermatol Venereol Leprol. 2021;87(3): 410–416. doi: https://doi.org/10.25259/IJDVL_374_19

19. Dănescu S, Leppert J, Cosgarea R, et al. Compound heterozygosity for dominant and recessive DSG1 mutations in a patient with atypical SAM syndrome (severe dermatitis, multiple allergies, metabolic wasting). J Eur Acad Dermatol Venereol. 2017;31(3):e144–e146. doi: https://doi.org/10.1111/jdv.13967

20. Pigors M, Schwieger-Briel A, Cosgarea R, et al. Desmoplakin mutations with palmoplantar keratoderma, woolly hair and cardiomyopathy. Acta Derm Venereol. 2015;95(3):337–340. doi: https://doi.org/10.2340/00015555-1974

21. Polivka L, Bodemer C, Hadj-Rabia S. Combination of palmoplantar keratoderma and hair shaft anomalies, the warning signal of severe arrhythmogenic cardiomyopathy: a systematic review on genetic desmosomal diseases. J Med Genet. 2016;53(5):289–295. doi: https://doi.org/10.1136/jmedgenet-2015-103403

22. Liang J, Li C, Zhang Z, et al. Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome caused by de novo mutation in the DSP gene misdiagnosed as generalized pustular psoriasis and treatment of acitretin with gabapentin. J Dermatol. 2019;46(7): 622–625. doi: https://doi.org/10.1111/1346-8138.14925

23. Savostyanov K, Murashkin N, Pushkov A, et al. Targeted NGS in Diagnostics of Genodermatosis Characterized by the Epidermolysis Bullosa Symptom Complex in 268 Russian Children. Int J Mol Sci. 2022;23(22):14343. doi: https://doi.org/10.3390/ijms232214343

24. Richard G. Autosomal Recessive Congenital Ichthyosis. 2001 Jan 10 [updated 2023 Apr 20]. In: GeneReviews® [Internet]. Adam MP, Feldman J, Mirzaa GM, et al, eds. Seattle (WA): University of Washington, Seattle; 1993–2024.

25. Sun Q, Burgren NM, Cheraghlou S, et al. The Genomic and Phenotypic Landscape of Ichthyosis: An Analysis of 1000 Kindreds. JAMA Dermatol. 2022;158(1):16–25. doi: https://doi.org/10.1001/jamadermatol.2021.4242

26. Murase Y, Takeichi T, Kawamoto A, et al. Reduced stratum corneum acylceramides in autosomal recessive congenital ichthyosis with a NIPAL4 mutation. J Dermatol Sci. 2020;97(1):50–56. doi: https://doi.org/10.1016/j.jdermsci.2019.12.001

27. Kondratenko IV, Bologov AA. Pervichnye immunodefitsity: Textbook. Moscow: IndeksMed Media; 2020. p. 31. (In Russ).

28. Kondratenko IV, Bologov AA. Pervichnye immunodefitsity: Textbook. Moscow: IndeksMed Media; 2020. pp. 117–120. (In Russ).

29. Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015;4(5):858–873. doi: https://doi.org/10.3390/jcm4050858

30. Murashkin NN, Opryatin LA, Epishev RV, et al. New Era in Atopic Dermatitis Treatment: Results of Long-Term Dupilumab Administration. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(5):390–395. (In Russ). doi: https://doi.org/10.15690/vsp.v20i5.2312

31. Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62(2):151–161. doi: https://doi.org/10.2332/allergolint.13-RAI-0564

32. Malik K, He H, Huynh TN, et al. Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol. 2019;143(2):604–618. doi: https://doi.org/10.1016/j.jaci.2018.03.021

33. Paller AS, Renert-Yuval Y, Suprun M, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139(1):152–165. doi: https://doi.org/10.1016/j.jaci.2016.07.019

34. Kuptsova DG, Radigina TV, Kurbatova OV, et al. Content of CD4+Т cell subpopulations in predicting the efficacy of biological therapy for psoriasis in children. Medical Immunology (Russia) = Meditsinskaya Immunologiya. 2023;25(5):1071–1078. (In Russ). doi: https://doi.org/10.15789/1563-0625-COC-2704

35. Tausend W, Downing C, Tyring S. Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis: Ustekinumab, Briakinumab, Tildrakizumab, Guselkumab, Secukinumab, Ixekizumab, and Brodalumab. J Cutan Med Surg. 2014;18(3):156–169. doi: https://doi.org/10.2310/7750.2013.13125.

36. Murashkin NN, Opryatin LA, Bridan-Rostovskaya AS, et al. Results of Combined Pathogenetic Therapy in Netherton Syndrome: Clinical Case. Voprosy sovremennoi pediatrii — Current Pediatrics. 2023;22(5):433–442. (In Russ). doi: https://doi.org/10.15690/vsp.v22i5.2621

37. Godsel LM, Roth-Carter QR, Koetsier JL, et al. Translational implications of Th17-skewed inflammation due to genetic deficiency of a cadherin stress sensor. J Clin Invest. 2022;132(3):e144363. doi: https://doi.org/10.1172/JCI144363

38. Hernández-Martín A, Kennedy-Batalla R, Cañedo E, et al. Imbalance in T-Helper 17 Cells and Targeted Therapy in an Infant with SAM-like Syndrome. N Engl J Med. 2019;381(22):2176–2178. doi: https://doi.org/10.1056/NEJMc1908531

39. Cao Q, Hou J, Pan C, et al. Successful Treatment of SAM Syndrome With Secukinumab Monotherapy: A Case Report of a 16-Month-Old Infant. Dermatitis. 2024;35(4):400–402. doi: https://doi.org/10.1089/derm.2023.0222

40. Frommherz LH, Schempp CM, Has C. Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency. Br J Dermatol. 2021;184(4):770–772. doi: https://doi.org/10.1111/bjd.19684